Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations

Table 5 Independent factors for pre-existing rtM204I variants in treatment-naïve chronic hepatitis B patients

	Pre-existing rtM204I (n = 17)	Wild type rtM204 (n = 386)	Univariate			Multivariate
			OR	95%CI	P value	OR	95%CI	P value
Gender (male)	14 (82.4%)	230 (59.6%)	3.165	(0.895-11.197)	0.074
Age, yr	48.8 ± 9.3	43.7 ± 12.6	1.033	(0.993-1.074)	0.105
HBeAg status (positive)	10 (58.8%)	228 (59.1%)	0.990	(0.369-2.656)	0.984
HBV-DNA, log10 IU/mL	6.33 ± 0.66	6.06 ± 1.77	1.098	(0.827-1.458)	0.519
qHBsAg, log10 IU/mL	3.43 ± 0.30	3.59 ± 0.70	0.555	(0.336-0.916)	0.021
AST, IU/L	104.7 ± 40.9	78.7 ± 65.2	1.005	(0.999-1.011)	0.109
ALT, IU/L	77.8 ± 29.4	85.4 ± 84.1	0.999	(0.992-1.005)	0.709
Total bilirubin, mg/dL	0.93 ± 0.33	0.88 ± 0.60	1.140	(0.522-2.487)	0.742
Albumin, g/dL	4.02 ± 0.43	4.14 ± 0.52	0.655	(0.275-1.559)	0.339
Prothrombin time, INR	1.07 ± 0.10	1.02 ± 0.16	4.625	(0.339-63.020)	0.250
Platelet count, × 103/mm3	155.7 ± 55.6	181.4 ± 64.4	0.993	(0.985-1.001)	0.108
Significant fibrosis1	12 (70.6%)	145 (37.6%)	3.989	(1.377-11.553)	0.011	3.397	(1.119-10.319)	0.031
Liver cirrhosis	7 (41.2%)	80 (20.7%)	2.677	(0.988-7.255)	0.053
HCC	5 (29.4%)	46 (11.9%)	3.080	(1.038-9.139)	0.043	1.961	(0.626-6.143)	0.248

¹Significant fibrosis was defined as aspartate aminotransferase to platelet ratio index > 1.5 or fibrosis-4 index > 3.25. ALT: Alanine aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4 Index; HCC: Hepatocellular carcinoma; INR: International normalized ratio; qHBsAg: Quantitative hepatitis B surface antigen levels; HBV: Hepatitis B virus.